Mumbai: 4baseCare announced a collaboration with AstraZeneca India for advancing cancer care in India. Under this collaboration, the two organisations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions.
Historically, most of these tests were unavailable locally and were imported burdening the cost of treatment. As a part of the collaboration, AstraZeneca and 4baseCare will work with the oncologist community to support a large number of patients by providing these services locally and also at a low cost ultimately increasing the chances of identifying optimal treatment options thereby improving clinical outcomes.
According to a report by ICMR on the ‘Burden of cancers in India’, seven cancers accounted for more than 40 per cent of the total disease burden; lung and breast cancer being the highest. The number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021. Given the advancement of technology in current times, patients have an opportunity to benefit significantly from various new age strategies including ‘Precision Oncology‘. It helps provide targeted therapy to patients by identifying which drugs would work best on which patient depending upon the unique biology of a patient’s disease. Genomics-based molecular profiling is the bedrock of targeted therapy and has proved to be a life-saving diagnostics tool as it helps identify the best medical intervention path while treating a patient.
Hitesh Goswami, CEO, 4baseCare points out, “There are 15 lakh new cancer patients diagnosed every year, and more than 60 per cent have advanced-stage cancer that can benefit from targeted therapy. 4baseCare’s vision is to make comprehensive genomic profiling as affordable and accessible as doing an MRI or PET scan is expensive. This technology could be used to guide and personalize treatment for every advanced-stage cancer patient.”
Dr Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India adds, “This will take us a step closer to strengthening the oncology ecosystem in the country thereby providing potential opportunities for improving long-term outcomes significantly.”